viral
diseas
lead
caus
death
worldwid
report
suggest
hepat
viru
hav
infect
popul
mani
develop
countri
viral
hepat
b
hbv
affect
estim
million
peopl
wherea
hepat
c
affect
million
peopl
worldwid
last
least
current
india
hivaid
popul
approxim
million
peopl
million
whole
world
becom
reason
million
death
global
thu
million
peopl
still
struggl
live
progress
medic
scienc
made
possibl
overcom
variou
fatal
diseas
small
pox
chicken
pox
dengu
etc
human
immunodefi
cienci
virus
infl
uenza
hepat
viru
renew
challeng
surprisingli
obstacl
challeng
therapi
includ
exist
antibiot
resist
strain
common
organ
due
overus
antibiot
lack
vaccin
advers
drug
reaction
last
least
suscept
concern
emerg
pharmacogenom
pharmacogenet
shown
promis
take
challeng
discoveri
human
genom
project
open
new
vista
understand
behavior
genet
makeup
develop
progress
diseas
treatment
variou
viral
diseas
current
previou
decad
engag
make
repositori
polymorph
snp
variou
gene
includ
drugmetabol
enzym
receptor
infl
ammatori
cell
relat
immun
antigenpres
cell
along
predict
risk
genet
makeup
alon
like
adequ
way
handl
therapeut
decisionmak
process
infecti
diseas
like
viral
number
one
caus
prematur
death
world
larg
number
antivir
drug
use
clinic
effect
erod
develop
resist
concern
safeti
research
area
led
fundament
discoveri
help
understand
reason
individu
differ
way
handl
drug
ultim
way
respond
drug
either
term
effi
caci
toxic
howev
much
knowledg
translat
clinic
practic
druggen
associ
evid
clinic
valid
progress
clinic
set
advanc
genom
sinc
explor
human
genom
provid
us
unpreced
opportun
understand
variabl
drug
respons
opportun
incorpor
patient
cure
need
newer
safer
antivir
drug
remain
continu
nowaday
explos
genom
sequenc
viral
pathogen
human
host
help
us
understand
complex
interact
involv
infect
process
pharmaceut
industri
exploit
inform
identifi
better
target
treat
viral
diseas
improv
understand
patient
respons
drug
socal
pharmacogenom
common
human
diseas
caus
virus
includ
common
cold
fl
u
chickenpox
cold
sore
seriou
diseas
ebola
hepat
aid
also
caus
virus
mani
virus
caus
littl
diseas
said
benign
harm
virus
describ
virul
virus
caus
differ
diseas
depend
type
cell
infect
virus
caus
lifelong
chronic
infect
virus
continu
reproduc
bodi
despit
host
defens
mechan
common
hepat
b
viru
hepat
c
viru
hiv
infect
hepat
occur
sporad
epidem
worldwid
tendenc
cyclic
recurr
lemon
epidem
uncommon
develop
countri
adult
gener
immun
poor
sanit
hygien
condit
differ
part
world
leav
larg
segment
popul
suscept
infect
outbreak
may
result
whenev
viru
introduc
lemon
melnick
shapiro
margoli
worldwid
hav
infect
account
million
case
annual
viral
hepat
prevent
board
hepat
b
viru
hbv
infect
seriou
global
health
problem
billion
peopl
infect
worldwid
million
suffer
chronic
hbv
infect
tenth
lead
previou
regimen
failur
introduct
new
antivir
therapeut
agent
signifi
cant
improv
progress
overal
surviv
achiev
drug
shown
sever
advers
respons
individu
success
expect
research
acquisit
new
knowledg
pharmacogenom
may
help
overcom
prevail
burden
viral
diseas
defi
nite
help
select
effect
therapeut
agent
effect
dose
drug
respons
individu
thu
abl
transform
laboratori
research
clinic
bench
side
also
help
understand
pathogenesi
viral
diseas
drug
action
patient
manag
properli
fi
nalli
becom
abl
fulfi
promis
futur
caus
death
worldwid
hbv
infect
result
million
death
per
year
caus
chronic
hepat
cirrhosi
hepatocellular
carcinoma
last
account
death
per
year
fact
sheet
hepat
b
viru
hbv
infect
major
global
public
health
problem
approxim
billion
peopl
infect
worldwid
million
act
chronic
carrier
hbv
fact
sheet
approxim
infect
patient
develop
cirrhosi
liver
failur
hepatocellular
carcinoma
lok
hbv
infect
account
million
death
year
mahoney
lee
tenth
lead
caus
death
worldwid
sinc
discoveri
hepat
c
viru
hcv
recogn
major
caus
chronic
liver
diseas
worldwid
recent
estim
preval
hcv
infect
repres
million
peopl
perz
et
al
hcv
lead
caus
liver
transplant
develop
countri
common
chronic
bloodborn
infect
usa
wide
rang
preval
estim
among
develop
countri
gener
less
data
avail
valid
assumpt
burden
diseas
develop
world
rang
preval
refl
ect
review
estim
develop
countri
among
world
popul
nation
popul
refer
bureau
china
whose
citizen
account
onefi
fth
world
popul
report
seropreval
xia
et
al
india
hold
addit
onefi
fth
world
popul
one
communitybas
survey
report
overal
rate
chowdhuri
et
al
countri
highest
report
preval
rate
locat
africa
asia
area
lower
preval
includ
industri
nation
north
america
northern
western
europ
australia
popul
nation
develop
world
rel
low
rate
hcv
seropreval
includ
germani
palitzsch
et
al
canada
zou
et
al
franc
desenclo
australia
law
et
al
australian
censu
low
slightli
higher
seropreval
rate
report
usa
alter
et
al
japan
ohshima
et
al
itali
human
papillomaviru
hpv
caus
cervic
cancer
second
biggest
caus
femal
cancer
mortal
worldwid
estim
number
cervic
cancer
death
around
per
year
preval
genit
hpv
infect
world
around
million
genotyp
hpv
infect
human
mucos
area
upper
digest
tract
genit
tract
major
adenocarcinoma
cervix
squamou
cell
cancer
scc
vulva
vagina
peni
anu
caus
togeth
account
case
global
remain
due
highrisk
hpv
type
rel
import
differ
highrisk
type
vari
countri
region
type
greatest
contribut
cervic
cancer
region
hpv
also
associ
cancer
anu
head
neck
rare
recurr
respiratori
papillomatosi
children
case
cervic
cancer
estim
occur
year
occur
develop
countri
neither
populationbas
routin
screen
eg
papanicola
smear
test
optim
treatment
avail
highest
estim
incid
rate
cervic
cancer
occur
africa
central
south
america
asia
epidemiolog
studi
usa
report
popul
infect
genit
hpv
lifetim
transient
infect
persist
infect
confi
rmed
detect
hpv
dna
genit
sampl
mild
cytolog
sign
clinic
lesion
hpv
belong
famili
papovavirida
small
nonenvelop
icosahedr
virus
kbp
long
doublestrand
circular
dna
genom
papillomaviru
genom
compris
earli
late
gene
encod
earli
protein
late
protein
earli
protein
nonstructur
protein
involv
replic
transcript
genom
host
cell
tumor
transform
wherea
structur
capsid
protein
virion
lowgrad
cervic
dysplasia
correspond
product
infect
cell
activ
shed
viru
wherea
highgrad
dysplasia
cancer
produc
virion
viral
gene
express
cell
limit
oncogen
transcrib
randomli
integr
viral
dna
protein
thought
induc
cell
prolifer
disrupt
cell
cycl
regul
inactiv
rb
famili
protein
wherea
block
cell
apoptosi
direct
tumor
suppressor
protein
proteasom
prophylact
hpv
vaccin
candid
base
recombin
capsid
protein
aim
elicit
neutral
antivir
antibodi
protect
infect
therapeut
vaccin
candid
base
viral
oncogen
protein
without
aim
induc
cellmedi
immun
respons
elimin
transform
tumor
cell
advanc
promis
approach
prophylact
vaccin
involv
use
noninfecti
recombin
viruslik
particl
vlp
selfassembl
spontan
pentam
capsid
protein
two
prophylact
vaccin
candid
level
phase
iii
clinic
evalu
compani
fi
led
licensur
gsk
focus
bival
vlp
vaccin
candid
merck
develop
tetraval
vaccin
base
vlp
show
high
effi
caci
proofofprincipl
studi
manufactur
announc
result
show
almost
protect
highgrad
cervic
cancer
precursor
caus
hpv
type
women
age
year
hpv
infect
young
femal
temporari
littl
longterm
signifi
canc
seventi
percent
infect
gone
year
year
howev
infect
persist
infect
women
high
risk
develop
precancer
lesion
cervix
progress
invas
cervic
cancer
process
usual
take
year
provid
mani
opportun
detect
treatment
precancer
lesion
progress
invas
cancer
almost
alway
prevent
standard
prevent
strategi
appli
lesion
still
caus
consider
burden
necessit
prevent
surgeri
mani
case
involv
loss
fertil
develop
countri
cervic
screen
use
papanicola
pap
test
liquidbas
cytolog
use
detect
abnorm
cell
may
develop
cancer
abnorm
cell
found
women
invit
colposcopi
colposcop
inspect
biopsi
taken
abnorm
area
remov
simpl
procedur
typic
cauter
loop
commonli
develop
world
freez
cryotherapi
treat
abnorm
cell
way
prevent
develop
cervic
cancer
pap
smear
reduc
incid
fatal
cervic
cancer
develop
world
even
case
death
usa
cervic
cancer
substanti
mortal
resourcepoor
area
worldwid
estim
case
death
year
kahn
sever
infl
uenza
epidem
twentieth
centuri
caus
million
death
worldwid
includ
worst
epidem
american
histori
spanish
infl
uenza
outbreak
kill
season
infl
uenza
acut
viral
infect
caus
infl
uenza
viru
three
type
season
infl
uenza
b
c
type
infl
uenza
virus
type
subtyp
accord
differ
kind
combin
viru
surfac
protein
among
mani
subtyp
infl
uenza
virus
current
infl
uenza
subtyp
circul
among
human
infl
uenza
virus
circul
everi
part
world
type
c
infl
uenza
case
occur
much
less
frequent
b
infl
uenza
b
virus
includ
season
infl
uenza
vaccin
avian
infl
uenza
human
avian
infl
uenza
infecti
diseas
bird
spread
peopl
diffi
cult
transmit
person
person
almost
peopl
infect
close
contact
infect
bird
environ
peopl
becom
infect
mortal
rate
get
swine
infl
uenza
virus
siv
caus
diseas
human
howev
countri
report
case
human
infect
siv
human
infect
mild
virus
spread
peopl
viru
caus
infl
uenza
pandem
thought
origin
swine
exampl
siv
abl
spread
easili
among
peopl
also
caus
diseas
hiv
human
immunodefi
cienci
viru
viru
lead
acquir
immun
defi
cienci
syndrom
aid
cdc
estim
peopl
unit
state
contract
hiv
two
type
hiv
usa
unless
otherwis
note
term
hiv
primarili
refer
type
hiv
damag
person
bodi
destroy
specifi
c
blood
cell
call
cell
crucial
help
bodi
immun
defens
aid
late
stage
hiv
infect
person
immun
system
get
sever
damag
feel
diffi
culti
fi
ghting
diseas
certain
cancer
develop
certain
medic
peopl
hiv
could
progress
aid
year
time
cure
hiv
infect
despit
major
advanc
diagnos
treat
hiv
infect
case
aid
diagnos
death
among
peopl
live
hiv
report
usa
abovediscuss
diseas
continu
threaten
whole
world
insist
search
explor
new
medicin
concept
manag
would
possibl
peopl
may
live
long
diseasefre
free
econom
burden
understand
incred
complex
biolog
hiv
viru
essenti
build
effect
diagnost
drug
hiv
belong
class
virus
known
retrovirus
contain
ribonucl
acid
rna
genet
materi
wedemey
et
al
clinic
phase
iii
ii
respect
still
littl
prospect
effect
vaccin
agent
enorm
burden
death
due
viral
diseas
compel
scientist
virologist
think
forc
overcom
mortal
global
around
antivir
compound
clinic
use
target
variou
viral
diseas
half
drug
use
treatment
patient
hiv
infect
treatment
acut
infect
one
caus
sever
ill
includ
hemorrhag
fever
enceph
even
cancer
avail
drug
limit
effi
caci
caus
sever
side
effect
dykxhoorn
lieberman
hiv
proteas
cleav
gag
gagpropol
polyprotein
ten
vari
site
necessari
matur
viru
kohl
et
al
major
therapeut
target
antivir
drug
last
year
structurebas
drug
discoveri
effort
led
develop
nine
approv
competit
activ
site
proteas
inhibitor
pi
inhibitor
potent
antihiv
drug
essenti
compon
highli
activ
antiretrovir
therapi
haart
bartlett
et
al
develop
drug
resist
major
reason
failur
proteas
inhibitor
therapi
viru
accumul
mani
mutat
within
proteas
prevent
pi
bind
proteas
half
residu
within
proteas
mutat
differ
combin
lead
drug
resist
wu
et
al
drug
resist
defi
ned
clinic
set
point
administr
drug
longer
safe
treat
diseas
state
due
induc
chang
drug
target
inabl
drug
reach
target
antimicrobi
agent
clinic
resist
occur
minimum
inhibitori
concentr
mic
drug
given
microbi
strain
exce
concentr
drug
safe
administ
resist
drug
aris
mutat
gene
gene
cluster
acquisit
extrachromosom
dna
transpos
plasmid
carri
resist
gene
gene
upregul
target
upregul
effl
ux
mechan
one
studi
recent
suggest
peet
approach
combat
drug
resist
involv
select
resili
drug
target
lefebvr
schiffer
evolut
constrain
develop
robust
drug
nalam
schiffer
less
suscept
develop
resist
importantli
antivir
chemotherapi
plagu
rapid
develop
drug
resist
strain
result
high
rate
replic
virus
combin
low
fi
deliti
replic
genom
biggest
challeng
deal
variat
among
clade
capabl
establish
latent
infect
earli
phase
infect
mehandru
et
al
also
escap
ctl
sequestr
infect
cell
central
nervou
system
owe
infrequ
access
cell
cn
mcmichael
rowlandjon
increas
suscept
vaccin
individu
might
owe
vectorspecifi
c
immun
respons
make
cell
prone
hiv
infect
howev
recent
report
demonstr
role
vectorspecifi
c
cell
increas
suscept
hiv
infect
hutnick
et
al
mechan
tcell
exhaust
antivir
control
would
import
assess
vaccin
studi
ensur
gener
mainten
memori
cell
trautmann
et
al
report
hivspecifi
c
cell
induc
acut
hiv
infect
helper
function
get
compromis
malhotra
et
al
larg
sequenc
divers
envelop
glycoprotein
anoth
barrier
develop
vaccin
anoth
major
hurdl
achiev
balanc
immun
respons
vaccin
candid
like
epitop
less
well
conserv
clade
conserv
within
clade
capabl
elicit
cladespecifi
c
rather
crossreact
nab
clade
c
virus
seem
sensit
neutral
variant
clade
van
gil
et
al
clade
c
infect
preval
among
elit
neutral
simek
et
al
vaccin
candid
use
env
immunogen
abl
produc
bnab
bnab
long
region
seem
polyreact
nonhiv
antigen
lack
bnab
gener
attribut
autoreact
bnab
direct
toward
env
autoreact
antienv
bnab
induc
central
toler
mechan
result
remov
b
cell
produc
antibodi
epitop
specifi
citi
heavi
chain
bnab
clone
b
cell
mice
model
result
loss
b
cell
express
matur
igm
mice
verkoczi
et
al
anoth
hypothesi
emphas
bnab
immunogen
enough
induc
prolifer
b
cell
follow
fi
netun
bcell
receptor
antibodi
code
somat
hypermut
fi
netun
bcell
receptor
gene
necessari
maxim
specifi
citi
antibodi
antigen
harro
et
al
rais
concern
approach
use
conserv
env
epitop
vaccin
candid
bnab
gener
natur
infect
hiv
result
viru
clearanc
host
immun
system
develop
natur
immun
reinfect
spite
intens
sustain
immun
respons
humor
cellmedi
defens
hiv
abl
resist
erad
continu
deplet
cell
eventu
lead
clinic
progress
aid
even
evid
superinfect
second
hiv
isol
readili
occur
hivinfect
person
lead
emerg
recombin
viru
variant
gener
increas
viru
divers
mc
cutchan
et
al
integr
latent
provir
dna
genom
longliv
memori
cell
provid
persist
reservoir
viru
escap
immun
surveil
peterlin
trono
calcul
would
take
year
erad
reservoir
latent
infect
cell
window
opportun
hiv
vaccin
therefor
narrowli
limit
earli
stage
infect
viru
seed
lymphoid
organ
mucos
tissu
gallo
hiv
also
develop
multipl
mechan
circumv
host
immun
respons
includ
abil
downregul
major
histocompat
complex
mhc
class
molecul
minim
recognit
ctl
well
high
genet
evolut
rate
allow
evad
immun
respons
emerg
viral
ctl
feeney
et
al
neutral
antibodi
escap
variant
anoth
diffi
culti
develop
effect
hiv
vaccin
stem
fact
viru
envelop
glycoprotein
conceal
conserv
receptorand
coreceptorbind
site
crypt
mask
hypervari
loop
molecul
glycan
residu
wei
et
al
neutral
antibodi
induc
respons
primarili
target
hypervari
loop
molecul
rare
recogn
receptorbind
site
make
hard
gener
broadli
crossreact
neutral
antibodi
primari
viru
isol
patient
yang
et
al
lack
effi
caci
antibodi
respons
rais
monomer
vaccin
protect
hiv
infect
proven
beyond
doubt
world
fi
rst
two
phase
iii
clinic
trial
aid
vaccin
mascola
et
al
although
neutral
antibodi
administ
passiv
nonhuman
primat
provid
protect
experiment
shiv
infect
ferrantelli
et
al
howev
contrari
laboratoryadapt
viru
strain
use
coreceptor
strain
protect
chimpanze
could
readili
achiev
induc
neutral
antibodi
target
hypervari
loop
girard
et
al
primari
viru
isol
use
coreceptor
strain
diffi
cult
neutral
cast
doubt
possibl
vaccin
elicit
protect
infect
induct
neutral
antibodi
alon
view
problem
recent
vaccin
approach
focus
induct
cellular
immun
respons
mcmichael
hank
induct
cellular
immun
respons
hiv
especi
ctl
respons
although
abl
provid
steril
immun
protect
infect
hope
enabl
vaccin
control
viru
replic
follow
infect
reduc
viru
load
slow
progress
toward
diseas
reduc
probabl
secondari
transmiss
viru
howev
virus
reason
fulli
amen
approach
infl
uenza
retrovirus
herp
virus
slow
virus
rhinovirus
arbovirus
obstacl
use
vaccin
includ
multipl
serotyp
eg
rhinovirus
togavirus
antigen
chang
eg
infl
uenza
retrovirus
latent
infect
drug
resist
also
major
obstacl
treatment
hepat
c
viru
hcv
essenti
hcv
proteas
attract
therapeut
target
respons
cleav
least
four
site
along
viral
polyprotein
mani
proteas
inhibitor
current
clinic
trial
howev
multidrug
resist
widespread
aris
quickli
certain
studi
clearli
compar
cocryst
structur
substrat
cocryst
structur
inhibitor
complex
show
case
proteas
chellappan
et
al
altman
et
al
primari
drug
resist
occur
hcv
inhibitor
protrud
away
substrat
envelop
similarli
prolong
therapi
hbv
lamivudin
associ
increas
incid
viral
resist
low
effi
caci
undesir
side
effect
occurr
resist
hbv
mutat
remain
major
obstacl
clinic
applic
treat
hbv
infect
lau
et
al
hoofnagl
di
biscegli
need
altern
therapeut
approach
provid
impetu
develop
novel
therapeut
reagent
inhibit
hbv
replic
purpos
resist
test
make
avail
inform
assist
select
antiretrovir
regimen
like
achiev
maintain
viral
suppress
guidelin
come
result
hiv
drug
resist
test
perform
hivinfect
person
enter
clinic
care
whether
treat
immedi
aim
strategi
detect
chanc
transmit
resist
maximum
possibl
hivinfect
individu
receiv
antiretrovir
therapi
resist
test
perform
presenc
virolog
failur
ensur
adequ
perform
resist
test
rna
level
least
copiesml
time
test
although
guidelin
agre
resist
test
could
also
attempt
individu
rna
level
copiesml
howev
last
group
patient
chanc
amplifi
sequenc
markedli
lower
drug
resist
test
might
also
help
manag
suboptim
viral
load
reduct
howev
less
clear
addit
switch
new
antiretrovir
drug
could
help
achiev
viral
suppress
importantli
given
drug
resist
mutat
wane
treatment
interrupt
drug
resist
test
set
virolog
failur
perform
patient
take
hisher
antiretrovir
drug
within
week
discontinu
therapi
two
type
antiretrovir
resist
assay
current
avail
assist
clinician
assess
hiv
resist
genotyp
assay
phenotyp
assay
hanna
daquila
hirsch
et
al
two
test
also
mark
use
sampl
rna
level
copiesml
tabl
show
common
assay
along
advantag
disadvantag
test
limit
sensit
detect
minor
variant
viral
popul
detect
nonb
subtyp
may
limit
test
last
least
result
requir
expert
interpret
addit
genotyp
test
use
gener
predict
phenotyp
refer
virtual
phenotyp
virtual
phenotyp
viral
sequenc
genotyp
enter
databas
consist
pair
genotyp
phenotyp
order
deriv
estim
phenotyp
recent
investig
employ
newer
techniqu
allelespecifi
c
pcr
singlegenom
ultradeep
sequenc
assess
role
minor
hiv
variant
harbor
drug
resist
detect
current
standard
genotyp
phenotyp
assay
hirsch
et
al
tabl
show
recent
advanc
resist
test
minor
level
identifi
es
mutat
predomin
viral
quasispeci
viral
popul
measur
overal
effect
mutat
assess
nonbclad
strain
potenti
measur
viral
tropism
replic
capac
parallel
longterm
drug
respons
determin
fail
account
interact
drug
combin
therapi
straightforward
interpret
highli
complex
test
platform
longer
turnaround
time
increas
cost
virtual
phenotyp
patternmatch
algorithm
use
larg
genotypicphenotyp
correl
databas
infer
phenotyp
properti
base
sequenc
data
known
mutat
use
match
new
sequenc
sequenc
alreadi
databas
includ
tabul
number
match
databas
drug
distribut
phenotyp
fold
increas
match
sampl
predict
power
depend
number
match
data
set
avail
thu
variat
frequent
higher
smaller
data
set
well
newer
drug
complex
resist
pattern
provid
quantit
predict
drug
resist
match
base
preselect
codon
entir
nucleotid
sequenc
show
good
correl
drug
thu
current
emerg
techniqu
like
sequenc
microarray
realtim
pcr
revolution
modern
concept
medicin
ie
wellknown
person
medicin
concept
treatment
base
individu
genom
composit
well
genet
makeup
infect
agent
strain
one
import
aspect
person
medicin
patienttopati
variat
drug
respons
pharmacogenom
address
issu
seek
identifi
genet
contributor
human
variat
drug
effi
caci
toxic
viral
diseas
go
discuss
current
updat
success
challeng
fi
eld
evolv
studi
singl
candid
gene
comprehens
genomewid
analys
thu
new
fi
eld
ultim
open
new
vista
understand
better
manag
fatal
viral
diseas
effect
person
clinic
treatment
strategi
may
develop
ultim
goal
person
medicin
take
advantag
molecular
understand
diseas
optim
drug
develop
direct
prevent
resourc
therapeut
agent
right
popul
peopl
still
well
goal
person
medicin
drug
develop
includ
select
optim
drug
target
select
optim
drug
dosag
select
monitor
patient
shorter
lessexpens
advanc
clinic
trial
abil
predict
individu
respond
drug
high
rate
less
like
suffer
toxic
side
effect
reduc
overal
cost
drug
develop
increas
drug
valu
ultim
improv
provid
effect
healthcar
individu
whether
well
suffer
earli
late
stage
ill
genet
variant
use
predict
predisposit
individu
futur
diseas
develop
appli
principl
person
medicin
possibl
signifi
cantli
enhanc
product
drug
discoveri
develop
identifi
cation
target
gene
appropri
pathway
suitabl
drug
develop
defi
nite
help
combat
viral
diseas
recent
emerg
progress
molecular
biolog
techniqu
make
rout
easier
select
right
target
variou
tradit
modern
genom
approach
nowaday
practic
thu
one
major
challeng
identifi
character
target
essenti
viru
surviv
absent
signifi
cantli
diverg
mammalian
host
may
sort
drug
discoveri
viral
diseas
small
genom
rel
viral
protein
make
process
fairli
straightforward
modern
molecular
techniqu
like
realtim
pcr
microarray
nextgen
sequenc
approach
current
give
precis
specifi
c
result
thu
help
progress
newer
therapeut
approach
tabl
show
variou
molecular
techniqu
target
select
quantit
analysi
base
viral
load
assay
viral
load
assay
express
copi
number
given
unit
plasma
usual
use
copiesml
altern
express
intern
unit
suggest
iuml
base
interlaboratori
standard
use
three
fdaapprov
viral
load
kit
exchang
relationship
copiesml
iuml
viral
load
dynam
rel
paramet
valu
chang
depend
method
use
fl
uctuat
even
daili
basi
varianc
repeat
test
use
kit
usual
smaller
determin
differ
method
thu
dynam
comparison
viral
load
valu
use
assay
method
time
strongli
suggest
hiv
viral
load
multipl
clinic
implic
report
global
aid
epidem
torti
et
al
firstli
current
serv
complementari
diagnosi
hiv
infect
may
becom
one
diagnosi
standard
near
futur
qualit
determin
hiv
infect
higher
viral
load
valu
measur
confi
dent
diagnosi
hiv
infect
drawn
exampl
viral
load
higher
copiesml
probabl
hiv
infect
individu
sampl
taken
signifi
cantli
high
particularli
high
viral
load
repeat
anoth
sampl
taken
individu
differ
time
secondli
viral
load
help
earli
diagnosi
hiv
infect
report
viral
burst
blood
earli
stage
hiv
infect
viral
load
earli
stage
sometim
even
higher
diseas
stage
aid
viral
load
assay
also
use
complementari
diagnosi
hiv
infect
neonat
hivinfect
mother
although
antibodybas
hiv
assay
diagnosi
standard
clinic
practic
useless
window
period
earli
stage
infect
diagnost
valu
infant
hivinfect
mother
discuss
earlier
thirdli
analysi
viral
load
effici
paramet
assess
antivir
therapi
effect
standard
viral
load
decreas
least
log
log
antivir
therapi
viral
load
reduc
copiesml
therapi
final
viral
load
valu
predict
progress
aid
exampl
viral
load
predict
probabl
p
valu
becom
aid
year
patient
normal
count
p
valu
viral
load
less
copiesml
p
valu
dramat
increas
viral
load
copiesml
count
less
viral
load
use
predict
shorter
progress
aid
probabl
turn
aid
within
month
viral
carrier
proport
associ
viral
load
valu
similar
conclus
drawn
recent
clinic
trial
includ
hivinfect
patient
haart
torti
et
al
patient
higher
tcell
count
follow
treatment
appear
surviv
month
wherea
increas
hiv
rna
copiesml
three
method
current
employ
commerci
kit
viral
load
assay
rtpcr
b
dna
nasbabas
assay
tabl
show
comparison
three
fdaapprov
viral
load
assay
commonli
use
assess
advantag
disadvantag
major
differ
assay
requir
specifi
c
equip
rather
sensit
specifi
citi
therefor
resourc
variou
set
remain
sequenc
bulk
errorpron
determin
factor
choos
pcrbase
hybridizationbas
isotherm
amplifi
cationbas
hiv
detect
assay
polymeras
chain
reaction
pcr
rtpcrbase
assay
frequent
use
technolog
molecular
biolog
molecular
diagnost
pcrbase
assay
use
either
qualit
quantit
analysi
hiv
hiv
retroviru
pcr
rtpcr
use
qualit
assay
viral
infect
target
integr
form
proviru
free
hiv
respect
rtpcr
howev
specifi
calli
requir
hiv
viral
load
assay
amplifi
ed
product
pcr
rtpcr
visual
varieti
method
agaros
gel
electrophoresi
realtim
visual
enzymat
reaction
one
commerci
kit
amplicor
use
enzymat
reaction
product
visual
micropl
platform
murphi
et
al
consid
complic
procedur
amplicor
assay
postamplifi
cation
hybrid
enzymat
reaction
visual
involv
multipl
step
mani
type
reagent
realtim
visual
advantag
develop
new
rtpcrbase
assay
hiv
viral
load
analysi
steven
et
al
simplic
shorter
time
requir
fi
nish
test
make
rtpcrbase
hiv
viral
load
assay
competit
among
avail
kit
possibl
one
focu
futur
kit
develop
amplifi
ed
product
nucleic
acidbas
method
electrophoret
analyz
fl
uoresc
visual
realtim
pattern
singlemolecul
identifi
cation
nonspecifi
c
fl
uoresc
dye
sybr
green
chosen
current
clinic
pharmacolog
laboratori
use
approach
highfi
deliti
dna
polymeras
differ
taq
polymeras
exonucleas
activ
former
exonucleas
activ
proofread
function
latter
exonucleas
activ
differ
differenti
employ
realtim
visual
pcramplifi
ed
product
taq
polymeras
use
taqman
technolog
wherea
realtim
visual
assay
use
mutationsensit
onoff
switch
mediat
highfi
deliti
dna
polymeras
depend
molecular
beacon
fret
molecular
beacon
structur
targetindepend
sequenc
design
end
primer
molecular
beacon
mix
targetspecifi
c
sequenc
loop
targetindepend
sequenc
hairpin
mix
beacon
add
one
short
fragment
identifi
ed
thu
help
enhanc
specifi
citi
assay
similarli
combin
mutationsensit
onoff
switch
fret
technolog
also
add
addit
sequenc
fragment
discrimin
test
mutationsensit
onoff
switch
offer
high
sensit
specifi
citi
nucleic
acid
identifi
cationmut
detect
combin
fl
uoresc
realtim
visual
make
highli
competit
technolog
develop
qualit
quantit
assay
hiv
infect
genet
variat
like
contribut
substanti
variat
drug
respons
observ
across
human
popul
fi
eld
pharmacogenom
relat
genet
variabl
variabl
human
drug
respons
evolv
consider
candid
gene
studi
studi
variat
across
whole
genom
human
popul
contain
individu
exhibit
rang
respons
differ
drug
initi
success
fi
eld
often
identifi
cation
genet
variant
within
drugmetabol
gene
larg
effect
sensit
given
drug
fi
eld
sinc
broaden
scope
encompass
regulatori
mutat
refi
ned
techniqu
made
us
abl
identifi
mutat
smaller
effect
size
wherea
earli
pharmacogenom
studi
sought
primarili
identifi
associ
common
genet
variat
drug
respons
recent
approach
begun
identifi
mrna
mirna
downstream
event
infl
uenc
genet
variat
may
underli
variat
pharmacolog
respons
primari
aim
pharmacogenom
uncov
novel
human
genet
variant
affect
therapeut
respons
phenotyp
identifi
gene
respons
phenotyp
differ
ultim
goal
fi
eld
use
understand
relat
devis
novel
person
pharmacolog
treatment
strategi
maxim
potenti
therapeut
benefit
minim
risk
advers
effect
given
medic
advanc
dna
sequenc
polymorph
character
technolog
enabl
fi
eld
evolv
sole
relianc
hypothesisdriven
approach
use
discoveryori
genomewid
approach
requir
fewer
priori
assumpt
regard
genet
variant
candid
gene
approach
result
primarili
identifi
cation
genet
variant
drugmetabol
gene
larg
effect
toxic
respons
weinshilboum
sladek
howev
mani
genomewid
associ
studi
gwa
identifi
novel
associ
drug
respons
genet
variant
unknown
function
relev
often
rel
small
effect
size
dali
recent
develop
highthroughput
sequenc
techniqu
enabl
research
begin
examin
contribut
rare
variant
drug
sensit
ramsey
et
al
genet
screen
hiv
predict
resist
recommend
expert
increasingli
use
clinic
set
hirsch
et
al
test
mutat
hiv
genom
predict
resist
done
therapi
failur
initi
regimen
genotyp
resist
test
judg
costeffect
even
rel
high
current
cost
test
weinstein
et
al
present
major
genet
resist
test
hiv
drug
involv
sequencebas
approach
howev
kitbas
test
expect
becom
common
test
cost
fall
automat
test
also
like
expand
beyond
viral
genom
addit
polymorph
host
genom
link
hiv
treatment
outcom
explor
applic
pharmacogenom
hiv
import
understand
underli
biolog
principl
genet
variat
human
genom
occur
predominantli
singlenucleotid
polymorph
snp
singl
nucleotid
differ
human
individu
dna
contain
mani
ten
million
snp
respons
divers
human
phenotyp
well
suscept
drug
diseas
twyman
scientist
approach
problem
identifi
catalog
character
snp
two
differ
angl
genom
approach
function
approach
genom
approach
involv
scientist
compar
genom
numer
individu
studi
differ
record
result
forum
dbsnp
short
genet
variat
databas
host
nation
center
biotechnolog
inform
ncbi
method
snp
character
requir
larg
amount
computerpow
data
analysi
unlik
function
approach
scientist
focu
select
gene
known
associ
particular
process
diseas
examin
across
popul
perelson
et
al
pharmacogenom
genet
variat
respect
drug
respons
studi
use
guid
patient
care
primari
bioinformat
resourc
pharmacogenom
pharmgkb
databas
develop
stanford
univers
studi
impact
genet
variat
drug
respons
focus
clinic
interpret
variant
drug
dose
guidelin
genet
test
inform
practic
applic
actor
health
sector
even
without
expand
number
drug
avail
howev
pharmacogenom
still
incred
impact
dose
prefer
exist
drug
employ
patient
care
fact
major
innov
alreadi
occur
resist
test
technolog
hiv
treatment
select
base
genom
genotyp
phenotyp
two
establish
method
identifi
antiretrovir
resist
patient
therapi
hiv
genotyp
discret
sequenc
revers
transcriptas
proteas
gene
extract
rna
specimen
amplifi
ed
gener
cdna
amplicon
undergo
sequenc
softwar
system
call
opengen
align
sequenc
report
mutat
produc
interpret
report
interpret
provid
insight
though
regard
degre
resist
drug
output
either
evid
resist
possibl
resist
resist
insuffi
cient
evid
hiv
drug
resist
databas
also
play
key
role
provid
advanc
inform
clinician
import
databas
often
use
hiv
genet
research
lo
alamo
hiv
drug
resist
databas
stanford
hiv
rt
proteas
sequenc
databas
former
collect
sequenc
focus
annot
data
analysi
recent
studi
prepar
databas
contain
compil
nearli
publish
hiv
revers
transcriptas
proteas
sequenc
link
data
sourc
sequenc
sampl
antiretrovir
drug
treatment
histori
individu
isol
obtain
shafer
anoth
group
develop
hivbas
softwar
solut
help
research
effect
manag
dnaamino
acid
sequenc
relat
geneticclin
data
use
storag
queri
capabl
salemi
store
genotyp
resist
data
link
clinic
inform
import
tool
success
diseas
manag
exampl
system
identifi
mutat
pattern
associ
resist
virodec
roch
diagnost
viroscor
abl
publish
diagnost
websit
virodec
hiv
onlin
applic
engin
upload
analyz
interpret
deliv
store
genet
sequenc
data
genotyp
assay
viroscor
hiv
resist
sequenc
manag
system
sequenc
databas
use
analysi
toolsalgorithm
resist
interpret
despit
advanc
technolog
interpret
still
limit
resist
test
systemat
approach
develop
predict
phenotyp
base
mutat
pattern
complic
complex
mutat
pattern
resist
mutat
snp
hbv
also
studi
detail
frequent
observ
precor
mutat
g
transvers
nucleotid
substitut
introduc
translat
stop
codon
tag
distal
precor
gene
prevent
express
precc
fusion
protein
function
precursor
hbeag
carman
et
al
less
common
precor
mutat
result
hbeag
neg
includ
initi
codon
mutat
posit
nonsens
mutat
missens
mutat
frame
shift
mutat
kramvi
et
al
stop
codon
mutant
often
present
patient
chronic
activ
inact
hepat
asymptomat
carrier
mediterranean
orient
countri
lee
et
al
mutat
may
occur
associ
mutat
mutat
associ
hbeag
neg
anoth
mutat
improv
stabil
provid
addit
u
base
pair
kramvi
et
al
stop
codon
mutat
also
present
high
proport
patient
fulmin
hepat
b
observ
initi
suggest
causal
role
mutant
maruyama
et
al
core
gene
contain
humor
cytotox
tcell
epitop
bertoletti
et
al
mutat
within
immunodomin
cytotox
tcell
epitop
may
exploit
virus
evad
protect
immun
respons
critic
viral
clearanc
delet
core
gene
report
immunocompromis
orient
patient
chronic
hepat
b
hepatocellular
carcinoma
yuan
et
al
delet
almost
alway
involv
loss
band
tcell
epitop
may
confer
select
advantag
viru
evad
immun
surveil
point
substitut
gene
particular
interest
affect
immunogen
hbsag
especi
determin
neutral
antibodi
rais
effort
explain
effect
mutat
one
region
exert
local
linearli
distant
epitop
origin
twoloop
model
determin
posit
carman
et
al
disulfi
de
bridg
amino
acid
recent
replac
cystein
web
model
mhr
posit
protein
carman
et
al
current
model
still
take
account
potenti
disulfi
de
bridg
addit
suppos
cystein
locat
web
structur
viral
envelop
two
loop
extern
virion
probabl
opposit
anoth
tight
loop
amino
acid
whole
mhr
divid
fi
antigen
region
name
posit
hbss
indic
loop
form
respect
spatial
close
mutant
found
studi
singapor
itali
japan
taiwan
indonesia
brunei
hsu
et
al
mutat
polymeras
gene
may
associ
resist
therapeut
effect
nucleosid
analogu
viral
persist
ononita
et
al
lamivudin
potent
inhibitor
rnadepend
dna
polymeras
hbv
irrevers
block
revers
transcript
inhibit
viral
replic
thu
effect
reduc
viral
burden
chronic
hbv
carrier
longterm
treatment
lamivudin
may
howev
lead
resist
result
gener
mutat
disrupt
ymdd
tyrosin
methionin
aspart
aspart
locu
c
domain
polymeras
gene
ling
et
al
mutat
consist
either
methionin
valin
methionin
isoleucin
substitut
mutat
result
amino
acid
substitut
codon
overlap
gene
lamivudineresist
variant
may
also
leucin
methionin
chang
b
domain
occur
often
associ
mutat
rare
mutat
chayama
et
al
substitut
effect
amino
acid
sequenc
gene
replic
effi
cienci
ymdd
mutant
less
wildtyp
viru
cessat
treatment
wildtyp
viru
reovertak
mutant
lamivudineresist
virus
remain
function
pathogen
famciclovir
prodrug
penciclovir
acycl
deoxyguanosin
analogu
penciclovir
inhibit
dnadepend
well
rnadepend
dna
polymeras
activ
similar
therapeut
effect
lamivudin
respons
emerg
mutant
usual
involv
b
domain
polymeras
gene
howev
mutant
resist
famciclovir
appear
less
common
induc
lamivudin
pichoud
et
al
x
gene
protein
exhibit
numer
activ
affect
intracellular
signal
transmiss
gene
transcript
cell
prolifer
dna
repair
apoptosi
arbuthnot
et
al
eightnucleotid
delet
end
gene
within
core
promoterenhanc
ii
cpenii
region
posit
fukuda
et
al
delet
okamoto
et
al
studi
describ
hbsagand
hbeagneg
patient
delet
shown
downregul
prec
promot
may
reason
suppress
hbv
protein
secret
core
promot
play
central
role
hbv
replic
morphogenesi
direct
transcript
pregenom
rna
precor
mrna
overlay
end
x
gene
end
precc
gene
sequenc
variat
core
promot
limit
pivot
role
viral
replic
doubl
mutat
transvers
g
transit
often
present
patient
chronic
hepat
hepatocellular
carcinoma
fulmin
hepat
less
often
asymptomat
carrier
immunosuppress
patient
carrier
without
hbv
marker
kramvi
kew
mutant
inextric
bound
evolut
chronic
may
import
hepatocarcinogenesi
develop
fulmin
hepat
asymptomat
cours
clinic
import
hbv
surfac
antigen
variant
subject
sever
review
carman
individu
respons
drug
complex
interact
genet
nongenet
factor
genet
variant
drug
target
diseas
pathway
gene
drugmetabol
enzym
use
predictor
drug
effi
caci
toxic
one
million
snp
avail
genotyp
phenotyp
studi
durbin
et
al
novel
genotyp
strategi
emerg
regular
basi
use
varieti
techniqu
design
increas
rate
data
gener
analysi
highresolut
snp
map
recent
develop
snp
consortium
http
snpcshlorg
could
expedit
identifi
cation
gene
complex
viral
diseas
hivaid
hepat
virolog
snp
technolog
focus
detect
predisposit
predict
toxic
respons
drug
select
best
individu
combin
antiretrovir
drug
snp
detect
use
predict
advers
event
antiretrovir
therapi
patient
hiv
infect
abo
et
al
potenti
clinic
valu
pharmacogenet
approach
predict
drug
toxic
uncov
candid
polymorph
discov
applic
genotyp
strategi
predict
antiretrovir
drug
effi
caci
recent
emerg
varieti
clinic
set
genotyp
resist
test
hiv
isol
demonstr
clinic
use
provid
way
assist
therapeut
decis
make
patient
whose
hiv
rna
level
rise
klein
et
al
moreov
hiv
viral
load
test
serv
major
guid
select
mainten
antiretrovir
therapi
sagreiya
et
al
develop
print
spot
genom
microarray
enabl
rapid
accumul
new
inform
concern
gene
mutat
express
human
microarray
use
gene
mutat
snp
well
provid
rapid
screen
inform
regard
mrna
express
transcript
profi
ling
abil
gener
hundr
thousand
data
point
requir
sophist
complex
inform
system
necessari
accur
use
data
analysi
techniqu
gener
wealth
new
inform
drug
biomark
target
discoveri
pharmacogenom
drug
effi
caci
test
highli
activ
antiretrovir
therapi
although
result
dramat
suppress
viral
replic
also
furnish
strong
select
forc
emerg
drugresist
variant
distribut
polymorph
extrem
exampl
examin
revers
transcriptas
rt
proteas
structur
variant
databas
modul
establish
structur
bioinformat
sbi
http
wwwstrubixcom
quest
diagnost
http
wwwquestdaignosticscom
reveal
two
patient
exactli
sequenc
individu
patient
exhibit
uniqu
sequenc
structur
variant
drug
target
princip
compon
determin
drug
effi
caci
distribut
drugtarget
structur
variant
within
patient
popul
chander
et
al
well
known
carcinogen
human
papillomavirus
hpv
causal
agent
cervic
cancer
hpv
infect
extrem
common
rel
rare
cancer
incid
indic
mani
infect
spontan
resolv
schiffman
et
al
persist
without
progress
host
genet
factor
may
play
role
cervic
carcinogenesi
thought
infl
uenc
develop
persist
hpv
infect
perhap
progress
cancer
czene
et
al
hemminki
chen
hemminki
et
al
hussain
et
al
hildesheim
wang
carrington
et
al
role
host
genet
factor
cofactor
associ
cervic
cancer
summar
tabl
discuss
safaeian
et
al
particularli
interest
stepwis
pathogenesi
diseas
extens
studi
initi
hpv
infect
cervic
transform
zone
subsequ
step
relat
viral
persist
progress
precanc
invas
schiffman
et
al
differ
factor
associ
step
toward
pathogenesi
role
nongenet
cofactor
persist
progress
well
studi
fewer
studi
host
genet
role
pathogenesi
cervic
cancer
current
therapi
chronic
viral
hepat
includ
two
regimen
ifn
antivir
nucleosidenucleotid
analogu
lamivudin
adefovir
dipivoxil
ribavirin
marcellin
et
al
chander
et
al
ifn
lamivudin
alon
control
hepat
b
onethird
patient
marcellin
et
al
liaw
combin
ifn
ribavirin
standard
therapi
hepat
c
result
erad
hcv
patient
chander
et
al
mchutchison
et
al
outcom
viral
therapi
infl
uenc
viral
load
viral
genom
variat
especi
viral
genotyp
certain
specifi
c
genom
variant
variou
therapeut
agent
show
variat
effi
caci
treatment
human
bodi
humor
ifn
serv
fi
rst
line
cellular
defens
control
viral
infect
ifninduc
molecul
lead
effect
control
viral
expans
either
inhibit
viral
replic
promot
infect
cell
undergo
apoptosi
supposedli
combin
molecul
person
determin
individu
vari
degre
respons
ifn
treatment
howev
gene
encod
molecul
conserv
human
certain
genet
polymorph
recent
gwa
articl
link
genotyp
ifnalpha
therapeut
respons
trigger
intens
research
establish
underli
mechan
associ
liapaki
jacobson
point
possibl
explan
strong
mechanist
clue
thio
thoma
specul
variant
correl
regul
cytokin
transcript
snp
locat
upstream
gene
thio
thoma
observ
cite
earlier
suppiah
colleagu
tanaka
colleagu
strongli
suggest
identifi
ed
snp
inde
alter
express
perhap
gene
suppiah
et
al
tanaka
et
al
two
studi
found
carri
g
risk
allel
snp
lower
mrna
express
cytokin
peripher
blood
mononuclear
cell
suppiah
et
al
tanaka
et
al
hand
ge
colleagu
report
differ
cytokin
express
peripher
blood
mononuclear
cell
hcvuninfect
person
homozyg
proxi
allel
snp
use
snpexpress
databas
ge
et
al
thu
variou
snp
show
variat
respons
tabl
show
signifi
cant
predictor
drug
respons
present
earlier
least
four
independ
gwa
studi
provid
signifi
cant
evid
role
gene
pathogenesi
hcv
infect
ge
et
al
suppiah
et
al
howev
still
piec
data
need
complet
mechanist
pictur
thio
thoma
gene
encod
one
recent
discov
type
iii
interferon
lambda
interferon
belong
superfamili
dellgren
et
al
type
iii
interferon
cytokin
murin
studi
reveal
preferenti
express
ifnlambda
receptor
epitheli
surfac
suggest
type
iii
interferon
may
allow
host
rapidli
elimin
virus
major
portal
entri
bodi
infect
establish
without
activ
arm
immun
system
ank
et
al
ank
et
al
ank
paludan
nonetheless
one
import
differ
establish
murin
human
system
interleukin
liapaki
jacobson
receptor
alpha
chain
receptor
complex
induc
ifnlambda
express
human
hepatocyt
wherea
murin
liver
seem
unlik
respond
ifnlambda
ank
et
al
ank
paludan
fi
nding
suggest
ifnlambda
contribut
host
defens
hepatotrop
virus
hcv
human
like
type
interferon
lambda
interferon
activ
hcv
viral
infect
vitro
vivo
marcello
et
al
howev
vitro
exogen
ifnlambda
induc
slower
sustain
abund
ifnstimul
gene
ifnalpha
marcello
et
al
although
fi
nding
answer
ifnlambda
might
play
key
role
hcv
recoveri
explain
treatmentassoci
resolut
hcv
infect
associ
certain
base
sequenc
locat
upstream
start
codon
cytokin
thio
thoma
addit
mechanist
question
profound
import
recent
gwa
fi
nding
genet
variat
predictor
outcom
patient
treat
hcv
infect
major
practic
implic
sever
recent
gwa
studi
demonstr
remark
associ
snp
near
within
region
gene
code
ge
et
al
suppiah
et
al
tanaka
et
al
rauch
et
al
result
promis
lead
import
mechanist
fi
nding
relat
ifn
respons
diseas
probabl
major
contribut
individu
medicin
therapeut
decis
make
ge
colleagu
suggest
near
futur
advanc
knowledg
genotyp
patient
infect
hcv
could
becom
import
compon
clinic
decis
initi
treatment
fi
nding
may
also
lead
individu
treatment
regimen
regard
chosen
medicin
durat
therapi
ge
et
al
suppiah
et
al
tanaka
et
al
rauch
et
al
moreov
critic
import
gene
region
mediat
respons
emphas
interest
develop
ifnlambda
therapeut
agent
patient
chc
doyl
et
al
pagliaccetti
et
al
instanc
earli
studi
pegyl
form
demonstr
promis
antivir
activ
potenti
benefi
reduc
hematolog
toxic
owe
hepatocytespecifi
c
receptor
profi
le
ifnlambda
versu
ifnalpha
doyl
et
al
pagliaccetti
et
al
recent
candid
gene
studi
welzel
colleagu
investig
associ
genet
hcv
treatment
respons
focu
ifnalpha
pathway
welzel
et
al
genotyp
snp
along
ifnalpha
pathway
patient
hepat
c
longterm
treatment
cirrhosi
haltc
trial
util
assay
appli
biosystem
carlsbad
ca
usa
analysi
abi
platform
appli
biosystem
focus
european
american
n
purpos
statist
power
welzel
et
al
particip
fi
brosi
score
previous
respond
ifn
treatment
without
rbv
childturcottepugh
score
less
seven
treat
pegifn
rbv
week
week
undetect
week
recent
studi
welzel
colleagu
examin
snp
gene
encod
ifnalpha
ifnalpha
receptor
jaktyrosin
kinas
stat
part
signal
transduct
via
jakstat
pathway
ifnalphainduc
gene
antivir
properti
includ
adenosin
deaminaseeukaryot
translat
initi
factor
kinas
resist
synthetas
well
interferon
regulatori
factor
welzel
et
al
recent
studi
ke
colleagu
extend
previou
research
appli
ann
algorithm
logist
regress
featur
select
predict
ifnalpha
rbv
treatment
outcom
use
genet
factor
cohort
chc
patient
origin
previou
studi
lin
addit
rapid
patientspecif
drugresist
phenotyp
manag
antiretrovir
therapi
structur
pharmacogenom
use
predict
clinic
trial
outcom
comput
analyz
interact
put
drug
sampl
polymorph
structur
repertoir
new
drug
encount
clinic
possibl
predict
bind
effect
new
drug
initi
expens
clinic
evalu
patient
straightforward
applic
extens
recent
report
success
comput
predict
drug
resist
phenotyp
proteas
patientbypati
basi
shenderovich
et
al
interact
movement
side
chain
individu
polymorph
structur
respons
drug
bind
comput
exampl
comparison
comput
structur
chang
upon
drug
bind
observ
chang
correspond
xray
crystallograph
structur
hong
et
al
saquinavirhiv
proteas
complex
sensit
specifi
citi
predict
drug
resist
phenotyp
patientbypati
basi
variou
food
drug
administr
fda
http
wwwfdagov
approv
drug
base
upon
comput
rel
energi
e
bind
interact
drug
patient
uniqu
drugtarget
polymorph
structur
number
appear
quit
good
comparison
achiev
laboratori
present
howev
perhap
import
respect
increas
effi
cienci
speed
drug
design
answer
gener
overnight
rather
week
typic
timefram
laboratori
drug
resist
phenotyp
anoth
way
look
interact
put
drug
drug
lead
set
drugtarget
polymorph
dock
molecul
individu
polymorph
measur
distanc
drug
residu
within
protein
analysi
five
differ
proteas
inhibitor
shown
tabl
predict
drug
effi
caci
mutat
frequenc
profi
le
superimpos
bottom
graph
analysi
clearli
identifi
es
aminoacyl
side
chain
mutat
high
frequenc
close
proxim
bound
drug
proxim
stabl
distal
mutat
distal
stabl
structur
pharmacogenom
technolog
broad
applic
ration
design
highli
effect
infecti
diseas
therapi
bacteria
well
virus
drug
well
vaccin
offer
prospect
stabl
effi
caci
face
drug
select
pressur
addit
natur
occur
infecti
agent
clear
signifi
cant
valu
biodefenserel
applic
ration
drug
vaccin
design
threat
assess
predict
understand
manag
advers
effect
antiretrovir
therapi
highli
activ
antiretrovir
therapi
haart
chang
landscap
hiv
diseas
way
seem
unthink
decad
ago
fi
rst
haart
regimen
work
suppress
viru
encumb
varieti
shortterm
longterm
side
effect
recent
regimen
becam
simpler
easier
take
fewer
advers
event
knowledg
shortand
longterm
advers
event
associ
haart
essenti
provid
patient
new
drug
accept
current
fi
eld
pass
litmu
test
toler
sinc
advers
event
often
remark
idiosyncrat
pharmacogenom
may
offer
way
predict
side
effect
sever
particular
drug
drug
class
individu
patient
advers
event
ae
play
major
role
determin
adher
highli
activ
antiretrovir
therapi
haart
adher
perhap
signifi
cant
determin
random
control
clinic
trial
gold
standard
evalu
effi
caci
drug
may
underestim
shortterm
toxic
gener
clinic
popul
desir
subject
stay
trial
support
trial
staff
enabl
longterm
toxic
may
miss
often
younger
age
subject
clinic
trial
rel
shortterm
durat
trial
may
detect
toxic
low
preval
rate
tabl
show
advers
effect
associ
differ
class
antiretrovir
ae
antiretrovir
drug
use
divid
shortand
longterm
toxic
also
class
agent
use
consider
progress
made
identifi
mutat
associ
drug
resist
tabl
understand
mechan
confer
resist
tabl
varieti
mechan
identifi
ed
differ
differ
class
drug
drug
given
class
nucleosid
analogu
nucleotid
analogu
tabl
block
synthesi
viral
dna
revers
transcriptas
enzym
phosphoryl
cellular
kinas
compound
incorpor
revers
transcriptas
nascent
chain
viral
dna
drug
lack
hydroxyl
group
addit
nucleotid
attach
synthesi
viral
dna
arrest
two
distinct
mechan
involv
hiv
resist
drug
impair
incorpor
analogu
dna
remov
analogu
prematur
termin
dna
chain
sever
mutat
group
mutat
revers
transcriptas
enzym
promot
resist
select
impair
abil
revers
transcriptas
incorpor
analogu
dna
essenti
includ
mutat
complex
mutat
mutat
tabl
famili
mutat
known
thymidin
analogu
mutat
associ
resist
nucleosid
analogu
except
lamivudin
vitro
caus
highlevel
resist
zidovudin
lowlevel
resist
stavudin
didanosin
abacavir
segreg
two
pathway
one
compris
pathway
compris
associ
decreas
respons
tenofovir
observ
virus
resist
treatment
lamivudin
confer
highlevel
resist
lamivudin
vitro
interfer
resist
zidovudin
stavudin
number
thymidin
analogu
mutat
small
increas
level
resist
didanosin
abacavir
owe
thymidin
analogu
mutat
rare
pathway
resist
nucleosid
analogu
vitro
caus
highlevel
resist
nucleosid
analogu
except
lamivudin
tenofovir
insert
mutat
insert
two
amino
acid
usual
serin
next
codon
emerg
virus
alreadi
sever
thymidin
analogu
mutat
confer
highlevel
resist
nucleosid
analogu
select
zalcitabin
abacavir
tenofovir
therapi
select
abacavir
therapi
select
didanosin
therapi
usual
didanosin
nucleosid
analogu
mutat
confer
resist
nnrti
mutat
frequent
select
efavirenz
therapi
occasion
select
nevirapin
therapi
confer
highlevel
resist
avail
nnrti
mutat
frequent
select
nevirapin
confer
highlevel
resist
nevirapin
lowerlevel
resist
efavirenz
unlik
seen
mostli
efavirenz
therapi
mutat
accumul
prolong
ineffect
therapi
nnrti
proteas
gag
mutat
frequent
resist
mutat
observ
failur
therapi
proteas
inhibitor
mutat
frequent
select
saquinavir
therapi
common
resist
mutat
emerg
earli
failur
therapi
proteas
inhibitor
mutat
frequent
select
ritonavir
indinavir
therapi
mutat
frequent
select
nelfi
navir
therapi
alway
fi
rst
mutat
accumul
failur
therapi
proteas
inhibitor
caus
gradual
increas
level
resist
comment
revers
transcriptas
frequent
found
prolong
ineffect
therapi
proteas
inhibitor
associ
highlevel
resist
proteas
inhibitor
exclus
select
saquinavir
therapi
associ
highlevel
resist
saquinavir
emerg
occasion
failur
indinavir
therapi
also
found
lopinavir
therapi
often
select
amprenavir
therapi
also
found
lopinavir
therapi
rare
mutat
confer
highlevel
resist
proteas
inhibitor
mutat
gag
main
viral
substrat
proteas
increas
resist
partial
compens
resistanceassoci
loss
viral
replic
capac
mutat
design
accord
letter
wildtyp
amino
acid
subject
substitut
follow
turn
posit
amino
acid
revers
transcriptas
proteas
sequenc
letter
mutant
amino
acid
exampl
indic
methionin
posit
replac
valin
complet
descript
hiv
drugresist
mutat
latest
inform
interpret
found
http
hivdbstanfordedu
http
wwwiasusaorgresistancemutationsindexhtml
intern
aid
societyusa
mutat
affect
domain
glycoprotein
whose
interact
promot
membran
fusion
enfuvirtid
interfer
glycoprotein
membran
fusion
mutat
involv
replac
methionin
valin
posit
revers
transcriptas
main
mutat
confer
resist
lamivudin
boucher
et
al
methionin
locat
heart
catalyt
site
revers
transcriptas
replac
valin
differ
side
chain
interfer
proper
posit
lamivudin
triphosph
within
catalyt
site
sarafi
ano
et
al
mutat
induc
high
level
resist
lamivudin
lamivudin
use
singl
agent
resist
strain
overtak
wildtyp
viru
week
schuurman
et
al
lamivudin
use
part
fail
regimen
haart
mutat
almost
alway
fi
rst
mutat
emerg
havlir
et
al
group
mutat
refer
complex
iversen
et
al
tabl
often
select
cours
failur
regimen
contain
stavudin
didanosin
pathway
alway
start
substitut
residu
locat
immedi
vicin
nucleotidebind
site
revers
transcriptas
follow
gradual
accumul
secondari
mutat
enhanc
resist
increas
activ
enzym
kosalaraksa
et
al
complex
rel
rare
fewer
hiv
strain
resist
nucleosid
analogu
confer
highlevel
resist
eg
lamivudin
tenofovir
analogu
iversen
et
al
interestingli
complex
markedli
frequent
mutat
seen
increas
frequenc
patient
therapi
nucleosid
nucleotid
analogu
fail
especi
regimen
includ
tenofovir
abacavir
mutat
appear
confer
resist
analogu
except
zidovudin
remov
nucleosid
analogu
termin
dna
chain
associ
group
mutat
commonli
term
thymidin
analogu
mutat
tabl
mutat
group
frequent
select
failur
drug
combin
includ
thymidin
analogu
zidovudin
stavudin
promot
resist
almost
nucleosid
nucleotid
analogu
includ
tenofovir
larder
kemp
picard
et
al
mutat
occur
gradual
order
emerg
vari
thymidin
analogu
mutat
promot
resist
foster
atpor
pyrophosphatemedi
remov
nucleosid
analogu
end
termin
dna
strand
meyer
et
al
atp
pyrophosph
abund
normal
lymphocyt
particip
dnapolymer
reaction
structur
revers
transcriptas
express
thymidin
analogu
mutat
facilit
entri
site
adjac
incorpor
analogu
chamberlain
et
al
posit
atp
pyrophosph
attack
phosphodiest
bond
link
analogu
dna
result
remov
analogu
interestingli
effi
cienci
process
also
known
primer
rescu
signifi
cantli
decreas
presenc
mutat
revers
transcriptas
phenomenon
best
describ
case
mutat
larder
et
al
consequ
slow
select
thymidin
analogu
mutat
thymidin
analogu
picard
et
al
may
slightli
increas
residu
antivir
activ
nucleosid
analogu
spite
presenc
thymidin
analogu
mutat
nonnucleosid
revers
transcriptas
inhibitor
small
molecul
strong
affi
niti
hydrophob
pocket
locat
close
catalyt
domain
revers
transcriptas
bind
inhibitor
affect
fl
exibl
enzym
therebi
block
abil
synthes
dna
mutat
select
failur
treatment
nonnucleosid
revers
transcriptas
inhibitor
locat
pocket
target
compound
reduc
affi
niti
drug
esnouf
et
al
hsiou
et
al
subtl
differ
interact
variou
nonnucleosid
revers
transcriptas
inhibitor
hydrophob
pocket
howev
mutat
emerg
frequent
somewhat
drug
depend
tabl
resist
nevirapin
often
associ
mutat
mutat
also
occur
initi
resist
efavirenz
gener
character
mutat
mutat
also
seen
hiv
proteas
cleav
larg
polyprotein
precursor
specifi
c
site
releas
structur
protein
enzym
necessari
assembl
infecti
viral
particl
absenc
function
proteas
viral
particl
produc
immatur
infecti
proteas
hiv
symmetr
assembl
homodim
central
symmetr
substratebind
caviti
detail
knowledg
structur
domain
structur
natur
protein
substrat
enzym
led
design
specifi
c
inhibitor
whose
chemic
structur
mimic
viral
peptid
normal
recogn
cleav
proteas
robert
et
al
compound
display
strong
affi
niti
activ
site
hiv
proteas
inhibit
catalyt
activ
enzym
highli
select
manner
resist
proteas
inhibitor
consequ
amino
acid
substitut
emerg
either
insid
substratebind
domain
enzym
distant
site
molla
et
al
tabl
directli
indirectli
amino
acid
chang
modifi
number
natur
point
contact
inhibitor
proteas
therebi
reduc
affi
niti
enzym
hong
et
al
prabujeyabalan
et
al
exampl
common
resist
mutat
reduc
size
amino
acid
residu
proteas
import
bind
inhibitor
bind
natur
viral
protein
substrat
prabujeyabalan
et
al
proteas
inhibitor
design
bind
proteas
maxim
affi
niti
tend
occupi
space
insid
activ
site
caviti
natur
substrat
unlik
inhibitor
natur
substrat
proteas
variabl
gener
less
tight
interact
catalyt
site
phenomenon
promot
order
sequenti
cleavag
polyprotein
requir
proper
assembl
viral
particl
resist
mutat
proteas
result
overal
enlarg
catalyt
site
enzym
would
thu
predict
greater
effect
bind
inhibitor
natur
templat
mutat
select
certain
proteas
inhibitor
tabl
refl
ect
particular
chemic
structur
inhibitor
infl
uenc
interact
substratebind
domain
enzym
howev
consider
overlap
combin
mutat
hiv
strain
develop
resist
proteas
inhibitor
overlap
explain
wide
crossresist
gener
observ
within
drug
class
schapiro
et
al
remark
resist
proteas
inhibitor
also
promot
mutat
natur
viral
substrat
proteas
characterist
substitut
amino
acid
near
cleavag
site
gag
polyprotein
identifi
ed
increas
level
resist
replic
capac
viru
facilit
cleavag
condit
amount
activ
enzym
suboptim
improv
abil
proteas
contain
resist
mutat
interact
substrat
enter
target
cell
intric
sequenc
interact
hiv
envelop
glycoprotein
gp
complex
specifi
c
cellsurfac
receptor
kilbi
eron
earli
step
process
allow
fusogen
compon
complex
interact
cell
membran
therebi
tether
viru
target
membran
viru
target
cell
brought
close
proxim
foster
fusion
rearrang
step
distal
hydrophob
region
fold
onto
proxim
hydrophob
region
effect
shorten
molecul
enfuvirtid
peptid
deriv
destabil
process
bind
block
infect
viral
resist
enfuvirtid
usual
result
mutat
locat
stretch
ten
amino
acid
within
rimski
et
al
interestingli
chang
amino
acid
outsid
hr
even
chang
appear
associ
signifi
cant
differ
suscept
viru
enfuvirtid
mutat
polymorph
probabl
explain
remark
wide
rang
natur
suscept
enfuvirtid
among
strain
derdeyn
et
al
reev
et
al
could
particip
evolut
acquir
resist
enfuvirtid
crossresist
defi
ned
resist
drug
viru
never
expos
result
mutat
select
use
anoth
drug
crossresist
alway
restrict
drug
within
given
class
antiretrovir
agent
three
class
antiretrovir
drug
affect
earli
evolut
resist
nucleosid
analogu
proteas
inhibitor
virus
may
low
level
crossresist
altern
agent
within
two
class
drug
richman
nevertheless
strain
may
need
add
one
addit
mutat
preexist
scaffold
highlevel
crossresist
develop
therefor
patient
infect
strain
low
level
crossresist
switch
appar
activ
altern
drug
accompani
rapid
select
highli
resist
variant
expens
minim
evolutionari
chang
dulioust
et
al
resist
allornoth
phenomenon
gener
increas
time
richman
barbour
et
al
ross
et
al
singl
mutat
rare
produc
complet
resist
antiretrovir
drug
although
mutat
revers
transcriptas
result
complet
resist
lamivudin
except
rule
singl
mutat
hydrophob
pocket
revers
transcriptas
also
provid
strong
resist
nonnucleosid
revers
transcriptas
inhibitor
viral
strain
patient
regimen
use
drug
fail
often
incur
addit
mutat
suggest
level
resist
provid
singl
mutat
optim
hanna
et
al
resist
revers
transcriptas
inhibitor
accumul
thymidin
analogu
mutat
complex
mutat
resist
proteas
inhibitor
alway
gradual
process
lead
progress
increas
level
resist
mammano
et
al
nonetheless
even
sever
mutat
accumul
hiv
proteas
revers
transcriptas
suffi
cient
produc
patent
treatment
failur
resist
may
reach
maxim
level
addit
mutat
associ
increas
resist
occur
even
absenc
chang
treatment
barbour
et
al
inde
develop
complet
resist
may
repres
except
resist
mutat
impair
viral
replic
capac
solut
adopt
domin
viral
popul
may
entail
make
concess
term
resist
effort
made
evalu
antivir
activ
retain
individu
drug
face
resist
mutat
knowledg
may
help
treatment
patient
infect
virus
express
resist
multipl
class
drug
sinc
keep
hiv
pharmacolog
pressur
may
reduc
pathogen
potenti
mani
resist
mutat
impair
viral
replic
mutat
modifi
key
viral
protein
deleteri
effect
variabl
extent
protein
function
although
defi
cit
partial
correct
compensatori
mutat
nijhui
et
al
virus
forc
develop
higher
level
resist
intens
continu
pressur
antiretrovir
drug
often
substanti
impair
replic
capac
barbour
et
al
degre
replic
impair
confer
resist
mutat
highli
variabl
crippl
mutat
appear
associ
resist
proteas
inhibitor
zennou
et
al
signifi
cant
replic
defect
relat
mutat
revers
transcriptas
confer
resist
nucleosid
analogu
nonnucleosid
revers
transcriptas
inhibitor
back
et
al
bleiber
et
al
well
envelop
mutat
associ
resist
enfuvirtid
clinic
effect
resistanceassoci
loss
viral
replic
capac
subject
intens
investig
sever
observ
suggest
resist
virus
lost
virul
antiretrovir
treatment
interrupt
patient
infect
hiv
resist
multipl
drug
resist
strain
less
rapidli
replac
wildtyp
viru
chang
accompani
drop
tcell
count
suggest
wildtyp
viru
greater
replic
pathogen
potenti
deek
et
al
signifi
cant
proport
patient
haart
fail
tcell
count
remain
signifi
cantli
pretreat
level
despit
poor
control
replic
kaufmann
et
al
whether
appar
immunolog
benefi
haart
spite
patent
virolog
failur
direct
consequ
reduc
viral
pathogen
sign
persist
residu
activ
drug
regimen
remain
elucid
consequ
therapeut
strategi
take
advantag
resistanceassoci
loss
hiv
replic
capac
yet
identifi
ed
howev
recent
data
catch
usbas
studi
suggest
transmit
drugresist
hiv
remain
domin
popul
peripher
blood
extend
period
time
furthermor
studi
analyz
baselin
nucleotid
sequenc
among
subject
primari
hiv
infect
show
variat
antiretrovir
therapi
littl
et
al
patient
infect
approxim
day
least
one
major
drug
resist
mutat
longitudin
sampl
collect
median
day
infect
analyz
persist
transmit
drugresist
variant
seven
patient
evid
nnrti
resist
two
patient
resist
nrti
pi
one
patient
tripleclass
resist
averag
time
revers
variant
mix
nk
popul
seven
patient
nnrti
resist
day
follow
estim
date
infect
four
patient
mutat
confer
resist
proteas
inhibitor
revers
wild
type
detect
day
infect
complet
revers
genotyp
resist
observ
one
patient
day
infect
dr
kuritzk
conclud
data
present
croi
team
investig
gilead
scienc
borrotoesoda
et
al
studi
compar
oncedaili
emtricitabin
emtriva
oncedaili
stavudin
zerit
combin
didanosin
videx
efavirenz
sustiva
patient
north
america
latin
america
europ
overal
evalu
patient
enter
studi
hiv
mutat
posit
associ
resist
nnrti
differ
preval
type
mutat
group
subject
wildtyp
viru
baselin
incid
virolog
failur
stavudin
group
emtricitabin
group
among
patient
drugresist
viru
baselin
virolog
failur
occur
stavudin
group
emtricitabin
group
perhap
wide
cite
case
point
regard
danger
glaxosmithklin
trial
gallant
et
al
studi
patient
random
receiv
either
tenofovir
efavirenz
combin
fi
xeddos
combin
tablet
contain
mg
abacavir
mg
lamivudin
taken
day
patient
antiretrovir
therapi
prior
start
studi
averag
baselin
viral
load
copiesml
baselin
cell
count
cellsmm
glaringli
high
number
treatment
failur
document
triplenrti
group
studi
investig
conduct
unplan
analysi
involv
fi
rst
patient
complet
week
followup
approxim
patient
triplenrti
group
met
defi
nition
virolog
failur
compar
patient
efavirenzbas
arm
tenofovir
abacavir
lamivudin
select
mutat
among
patient
viral
load
high
enough
test
drug
resist
mutat
tenofovir
abacavir
lamivudin
exert
concert
pressur
locu
emerg
singl
mutat
abl
abrog
effi
caci
regimen
singl
stroke
nrti
exert
block
effect
plug
nonextend
nucleosid
analogu
monophosph
end
grow
provir
dna
chain
effect
termin
chain
extens
ultim
inhibit
replic
viru
howev
process
revers
revers
transcriptas
reaction
remov
chaintermin
residu
reinstat
extend
primer
revers
reaction
dna
polymer
term
pyrophosphorolysi
enabl
revers
transcript
dna
synthesi
resum
pyrophosphorolysi
enhanc
key
mutat
often
refer
thymidin
analogu
mutat
tam
pyrophosphorolysi
believ
primari
mechan
resist
zidovudin
stavudin
process
drug
specifi
c
way
discriminatori
mutat
tend
consequ
pyrophosphorolysisenhanc
mutat
confer
reduc
suscept
nrti
essenc
nrti
resist
sum
two
mechan
abil
alter
drug
bind
incorpor
mechan
describ
begin
section
plu
abil
alter
excis
drug
nascent
dna
chain
mutat
imped
drug
bind
primer
excis
effect
variant
harbor
tam
still
consid
rare
occurr
surpris
effect
mani
tam
fi
nger
domain
polymeras
make
deoxynucleotid
triphosph
bind
site
turn
tam
interfer
proper
function
enzym
imped
primer
excis
believ
sensit
hiv
nrti
affect
tam
notabl
zidovudin
also
note
tam
revers
effect
drug
bind
incorpor
data
suggest
concurr
zidovudin
use
prevent
emerg
mutat
though
mechan
respons
yet
elucid
interest
data
six
recent
clinic
trial
evalu
revers
transcriptas
inhibitor
regimen
contain
tenofovir
either
without
zidovudin
among
patient
initi
therapi
fi
rst
time
tenofovirinclus
regimen
involv
zidovudin
much
like
fail
associ
develop
mutat
convers
tenofovirand
zidovudineinclus
regimen
much
like
fail
associ
develop
tam
move
resist
issu
heavili
pretreat
hivposit
patient
dr
kuritzk
review
data
stem
actg
clinic
trial
design
determin
whether
addit
second
proteas
inhibitor
regimen
contain
amprenavir
ageneras
improv
respons
salvag
therapi
mellor
et
al
studi
enrol
heavili
pretreat
hivposit
patient
one
proteas
inhibitor
past
two
prior
proteas
inhibitor
past
three
proteas
inhibitor
past
approxim
patient
also
nnrti
past
patient
receiv
efavirenz
adefovir
dipivoxil
abacavir
amprenavir
addit
subject
random
receiv
either
placebo
nelfi
navir
viracept
saquinavir
fortovas
indinavir
crixivan
statist
signifi
cant
differ
three
activ
drug
arm
howev
signifi
cant
differ
combin
activ
arm
placebo
arm
demonstr
dual
proteas
inhibitor
regimen
superior
singl
proteas
inhibitor
regimen
heavili
pretreat
patient
surprisingli
actg
investig
report
nnrtinaiv
patient
significantli
better
respons
nnrtiexperienc
patient
nnrtiexperienc
patient
compar
nnrtinaiv
patient
fail
achiev
undetect
viral
load
week
followup
interest
though
analysi
nnrtiexperienc
patient
week
howev
differ
respons
rate
two
group
becam
insignifi
cant
eventu
converg
review
recent
work
area
thymidin
analogu
mutat
review
studi
result
explain
certain
tam
tend
occur
togeth
other
rare
found
togeth
viru
exampl
pathway
common
tam
pattern
associ
highlevel
resist
zidovudin
crossresist
nrti
includ
tenofovir
abacavir
contrast
pathway
isol
less
common
tam
pattern
associ
lower
fold
resist
cluster
also
show
mutat
rare
appear
revers
transcriptas
virus
also
harbor
mutat
mutat
kuritzk
diverg
tam
pathway
hu
et
al
nutshel
studi
found
isol
carri
mutat
replic
effi
cientli
isol
harbor
mutat
incorpor
mutat
isol
harbor
mutat
viral
fi
tness
substanti
reduc
convers
incorpor
mutat
isol
harbor
mutat
substanti
growth
advantag
presenc
zidovudin
hu
et
al
thu
conclud
pathway
common
confer
higherlevel
resist
zidovudin
nrti
wherea
virus
carri
lower
replic
capac
poorli
fi
respect
mutat
confer
signifi
cant
advantag
hiv
presenc
zidovudin
mutat
play
much
larger
role
develop
zidovudin
resist
usual
consid
kuritzk
perhap
bestknown
revers
transcriptas
mutat
known
caus
highlevel
resist
lamivudin
emtricitabin
howev
studi
suggest
highlevel
resist
lamivudin
necessarili
mean
drug
render
worthless
exampl
phenomenon
found
clinic
trial
partial
treatment
interrupt
conduct
dr
steven
deek
colleagu
deek
et
al
studi
focus
cohort
hivposit
individu
histori
excel
treatment
adher
drugresist
viremia
greater
copiesml
experienc
document
treatmentmedi
benefi
eg
viral
load
cell
count
pretreat
level
patient
either
stop
pi
nrti
determin
select
effect
two
drug
class
term
maintain
lessfi
viru
one
studi
discontinu
lamivudin
four
highli
treatmentexperienc
patient
viabl
altern
treatment
option
evid
mutat
regimen
consist
least
three
antiretrovir
campbel
et
al
six
week
stop
lamivudin
hiv
rna
level
increas
averag
copiesml
baselin
even
though
mutat
remain
detect
viru
patient
basic
show
us
even
presenc
mutat
lamivudin
still
contribut
hiv
rna
suppress
revers
wild
type
occur
four
patient
week
accompani
addit
averag
increas
viral
load
copiesml
upon
resum
lamivudin
therapi
mutat
reappear
within
week
four
patient
colat
trial
openlabel
trial
involv
patient
experienc
virolog
failur
lamivudinecontain
regimen
dragst
et
al
switch
anoth
regimen
approxim
half
patient
random
continu
lamivudin
therapi
remain
patient
random
discontinu
lamivudin
treatment
fortyeight
week
later
signifi
cant
differ
two
group
pharmacogenom
examin
infl
uenc
genet
variabl
drug
effi
caci
toxic
correl
gene
express
singlenucleotid
polymorph
patient
outcom
predict
studi
mallal
et
al
show
presenc
allel
highli
predict
hsr
abc
posit
neg
predict
valu
respect
use
genet
test
led
reduct
abcrel
hsr
ari
trial
squir
et
al
compar
rate
seen
trial
use
hla
screen
fi
rst
exampl
clinic
use
genet
screen
hiv
diseas
manag
get
widespread
approv
potenti
mutat
posit
signal
longer
halflif
increas
level
efavirenz
haa
et
al
haplotyp
within
associ
longer
halflif
nevirapin
chantarangsu
genet
variant
associ
gilbert
diseas
ugt
identifi
ed
part
haplotyp
four
variant
span
three
gene
gene
locu
lankisch
et
al
initi
assess
perform
small
cohort
patient
tdfassoci
renal
dysfunct
identifi
ed
singl
substitut
posit
gene
potenti
associ
side
effect
izzedin
et
al
exampl
nucleotid
variat
posit
human
pglycoprotein
gene
number
patient
genotyp
group
cc
ct
tt
still
experienc
virolog
suppress
month
respect
p
brumm
et
al
greater
patient
regimen
nrti
plu
pi
small
effect
though
signifi
cant
slower
time
immunolog
virolog
failur
cc
genotyp
pharmacogenom
provid
miracul
opportun
bring
chang
clinic
practic
medicin
health
due
upcom
research
fi
eld
also
help
minim
toxic
advers
effect
correl
newli
found
resist
mutat
histor
antiretrovir
use
could
interest
clinician
plan
subsequ
antiretrovir
regimen
patient
undergon
rang
treatment
molecular
diagnost
test
made
less
expens
make
abl
give
imper
therapi
viral
diseas
aidshiv
hepat
current
give
enorm
econom
burden
howev
happen
need
major
technolog
improv
abil
sequenc
screen
genom
dna
assess
individu
genom
context
popul
data
extens
populationbas
studi
requir
evalu
phenotyp
signifi
canc
acut
long
term
genom
variat
level
individu
variant
combin
variant
clinic
trial
must
carri
goal
identifi
outcom
variou
combin
genom
expressionbas
metabolom
proteom
data
arriv
complet
clinicogenom
profi
le
predict
diseas
risk
drug
respons
effort
jointli
open
new
ray
hope
miracul
chang
histori
medicin
peopl
suffer
viral
diseas
